Table 2.

Charges (e) of different regions based on sequence and molecular structure in 20 mM sodium acetate, pH 5.5. The protonation state of histidine is calculated from PROPKA 3.0 using the homology model. H1, H2, H3, L1, L2, and L3 indicate different CDR regions. CDR indicates the sum of the six CDR regions

mAbs	H1	H2	H3	L1	L2	L3	CDR	VH	CH1	hinge	CH2	CH3	VL	CL	Fv	Fc	mAb
Ganitumab IgG1	0	1	−1	1	1	1	3	4	6	1	4	2	1	1	5	12	38
Ganitumab IgG4P	0	1	−1	1	1	1	3	4	5	0	2	−1	1	1	5	2	24
Adalimumab IgG1	−2	1	−1	2	0	2	2	−2	5	1	4	2	5	1	3	12	32
Adalimumab IgG4P	−2	1	−1	2	0	2	2	−2	4	0	2	−1	5	1	3	2	18
Cetuximab IgG1	0	0	−2	1	−1	0	−2	2	5	1	4	2	−1	0	1	12	26
Cetuximab IgG4P	0	0	−2	1	−1	0	−2	2	4	0	2	−1	−1	0	1	2	12
Tremelimumab IgG1	0	−1	−1	0	0	0	−2	3	5	1	4	2	1	1	4	12	34
Tremelimumab IgG4P	0	−1	−1	0	0	0	−2	3	4	0	2	−1	1	1	4	2	20
Ipilimumab IgG1	0	−1	−1	1	1	0	0	3	6	1	4	2	1	1	4	12	36
Ipilimumab IgG4P	0	−1	−1	1	1	0	0	3	5	0	2	−1	1	1	4	2	22
Basiliximab IgG1	1	−1	−2	1	0	1	0	3	5	1	4	2	4	1	7	12	40
Basiliximab IgG4P	1	−1	−2	1	0	1	0	3	4	0	2	−1	4	1	7	2	26
Natalizumab IgG1	0	−1	−2	1	0	−1	−3	1	4	1	4	2	1	1	2	12	28
Natalizumab IgG4P	0	−1	−2	1	0	−1	−3	1	4	0	2	−1	1	1	2	2	16
Vesencumab IgG1	0	0	0	1	1	0	2	1	5	1	4	2	3	1	4	12	34
Vesencumab IgG4P	0	0	0	1	1	0	2	1	4	0	2	−1	3	1	4	2	20
Atezolizumab IgG1	−1	0	1	0	0	0	0	1	5	1	4	2	1	1	2	12	30
Atezolizumab IgG4P	−1	0	1	0	0	0	0	1	4	0	2	−1	1	1	2	2	16
Trastuzumab IgG1	0	0	−2	0	0	0	−2	1	6	1	4	2	2	1	3	12	34
Trastuzumab IgG4P	0	0	−2	0	0	0	−2	1	5	0	2	−1	2	1	3	2	20
TGN1412 IgG1	0	0	−1	1	2	0	2	2	5	1	4	2	4	1	6	12	38
TGN1412 IgG4P	0	0	−1	1	2	0	2	2	4	0	2	−1	4	1	6	2	24
Bevacizumab IgG1	0	−1	0	−1	1	0	−1	1	5	1	4	2	1	1	2	12	30
Bevacizumab IgG4P	0	−1	0	−1	1	0	−1	1	4	0	2	−1	1	1	2	2	16
Omalizumab IgG1	0	−1	2	−2	−1	−1	−3	3	5	1	4	2	−3	1	0	12	26
Omalizumab IgG4P	0	−1	2	−2	−1	−1	−3	3	4	0	2	−1	−3	1	0	2	12
Golimumab IgG1	0	−1	−1	1	0	1	0	3	6	1	4	2	1	1	4	12	36
Golimumab IgG4P	0	−1	−1	1	0	1	0	3	5	0	2	−1	1	1	4	2	22